Absolute rates for CV death
5.9% placebo VS 3.7% JARDIANCE
Absolute risk reduction
JARDIANCE DEMONSTRATED A 14% RRR FOR THE PRIMARY COMPOSITE ENDPOINT (HR=0.86 [95% CI: 0.74-0.99]; p=0.04)
- The absolute risk reduction for the composite endpoint was 1.6%
- There was no change in risk of nonfatal MI (HR=0.87 [95% CI: 0.70-1.09]) or nonfatal stroke (HR=1.24 [95% CI: 0.92-1.67]); the 14% RRR in CV events was due to a reduction in the risk of CV death (HR=0.62 [95% CI: 0.49-0.77])
*Glucose-lowering and CV medications.
†Pooled data from JARDIANCE 10 mg and JARDIANCE 25 mg; similar magnitude of reduction was shown with both doses.
CI=confidence interval; CV=cardiovascular; HR=hazard ratio; MI=myocardial infarction; RRR=relative risk reduction.
JARDIANCE CV Outcome Trial Design: A randomized, double-blind, parallel-group trial comparing the risk of experiencing a major adverse cardiovascular event between JARDIANCE and placebo when these were added to and used concomitantly with standard of care treatments for type 2 diabetes and cardiovascular disease. A total of 7020 patients were treated (JARDIANCE 10 mg [N=2345]; JARDIANCE 25 mg [N=2342]; placebo [N=2333]) and followed for a median of 3.1 years. All patients had established atherosclerotic cardiovascular disease at baseline, including one or more of the following: a documented history of coronary artery disease, peripheral artery disease, myocardial infarction, or stroke. The primary outcome was reduction in risk of cardiovascular events, defined by the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
Click below to explore other medication options